Protagonist Therapeutics Analyst Price Targets

SPY—QQQ—BTC/USD—DIA—GLD—TLT—

Premium

Protagonist Therapeutics Inc

PTGXNASDAQ

Trade with Public

$128.75

-7.80-5.71%

Last update: Oct 16, 4:28 PM

$128.75

-7.80-5.71%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Protagonist Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protagonist Therapeutics (PTGX).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

3S.Buy

15Buy

Consensus RatingBuy# Analysts18Avg. Consensus PT$135Upside to Avg. PT+4.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$184
Oct 12, 2026	Leerink Partners	Will Soghikian	Assumes	Outperform	$150→$190
Sep 1, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$153→$180
Sep 1, 2026	BMO Capital	Etzer Darout	PT Raise	Outperform	$178→$190
Aug 31, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$175→$182
Aug 31, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$167→$170
Aug 17, 2026	BMO Capital	Etzer Darout	PT Raise	Outperform	$112→$178
Aug 10, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$145→$170
Aug 10, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$118→$173
Aug 10, 2026	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$110→$186
Aug 6, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$130→$175
Aug 6, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$151→$153
Jul 14, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$119→$151
Jul 7, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$121→$145
May 10, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$125→$130
May 6, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$120→$137
May 6, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$112→$118
Apr 15, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$110→$121
Apr 7, 2026	Clear Street	Kaveri Pohlman	PT Raise	Buy	$104→$116
Mar 19, 2026	Leerink Partners	Faisal Khurshid	PT Raise	Outperform	$107→$110

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.

Benzinga Newsdesk

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.

Benzinga Newsdesk

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised

Avi Kapoor

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.

Benzinga Newsdesk

Protagonist Therapeutics Inc

Protagonist Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Protagonist Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

People Also Watch

People Also Watch

Protagonist Therapeutics Inc

Protagonist Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PROLeerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PROBarclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

PROBMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PROHC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Protagonist Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PROLeerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PROBarclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

PROBMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PROHC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170